Influence of amiodarone treatment on inflammation during cardiopulmonary bypass
© BioMed Central Ltd 2005
Published: 7 March 2005
Cardiopulmonary bypass (CPB) induces a systemic inflammatory response (SIRS), which causes significant morbidity or even mortality. Amiodarone (Amio) has shown to reduce postoperative atrial fibrillation and also to reduce tumor necrosis factor alpha (TNF-α) production in vitro. Whether Amio reduces the post CPB SIRS is unknown.
The present study sought to investigate the anti-inflammatory properties of Amio after CABG using CPB.
Twenty-two patients undergoing elective CABG were randomly assigned to receive 600 mg Amio orally 7 days pre surgery daily and 45 mg/hour intravenously for 48 hours after initiation of CPB (10 patients, group 2) or placebo (12 patients, group 1). Two patients in group 2 were excluded due to withdrawn consent during the loading phase. The primary endpoint was the C-reactive protein (CRP) curve (AUC) up to 96 hours, and secondary endpoints were fibrinogen and WBC up to 96 hours and TNF-α and IL-6 curves up to 48 hours post surgery, respectively.
In this pilot study, there was no difference in the post CPB inflammatory reaction between Amio-treated and placebo-treated patients.